Application of novel pH sensitive isoniazid-heptamethine carbocyanine dye conjugates against prostate cancer cells

Pharmazie. 2020 Sep 1;75(9):412-416. doi: 10.1691/ph.2020.0521.

Abstract

Recent studies have shown that monoamine oxidase A (MAOA) is significantly expressed in malignant prostate cancer (PCa) and plays an important role in tumorigenesis indicating its potential to serve as a target for PCa treatment. Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates. Cytotoxicity assay in PC-3 cells shows that all conjugates possessed improved antitumor efficacy compared with isoniazid. The tested compounds also demonstrated a moderate MAOA inhibitory effect. In conclusion, these results indicate that these conjugates exert antitumor effects by delivering the MAOA-inhibiting moiety to PCa cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Carbocyanines / chemistry*
  • Cell Line, Tumor
  • Drug Delivery Systems
  • Humans
  • Hydrogen-Ion Concentration
  • Isoniazid / administration & dosage
  • Isoniazid / chemistry
  • Isoniazid / pharmacology*
  • Male
  • Monoamine Oxidase Inhibitors / administration & dosage
  • Monoamine Oxidase Inhibitors / chemistry
  • Monoamine Oxidase Inhibitors / pharmacology*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Carbocyanines
  • Monoamine Oxidase Inhibitors
  • heptamethine cyanine dye
  • Isoniazid